SPI Pharmaceuticals

Reintroduces vitiligo drug Benoquin following receipt of supplemental approval of manufacturing and testing procedures. The prescription depigmenting agent monobenzone cream 20% became unavailable in 1990 when the bulk supplier discontinued production; SPI now has a new supplier. The product has been available for the last 10 months under an FDA Emergency IND. The company is notifying 7,100 dermatologists nationwide of Benoquin's availability.